We report a case of axillary arterial bleeding after administration of bevacizumab plus paditaxel in a patient with recurrent breast cancer. A 50-year-old woman with invasive ductal carcinoma of the left breast underwent mastectomy and sentinel node biopsy. She was administered 4 courses of docetaxel and cyclophosphamide as adjuvant chemotherapy. Twenty-eight months after the surgery, she developed axillary lymph node recurrence with pain and upper-limb paralysis. Initially, radiation therapy was performed in the axilla combined with the oral administration of TS-1. However, the response was inadequate. Subsequently, bevacizumab plus paditaxel was administered. After 2 courses, we observed remarkable shrinkage of the axillary tumor. However, she experienced massive bleeding from the axillary artery. As the bleeding recurred, we ligated the axillary artery. Caution is required while administrating bevacizumab in cases of tumors located close to the major blood vessels.
|Number of pages||3|
|Journal||Japanese Journal of Cancer and Chemotherapy|
|Publication status||Published - Jan 2020|
All Science Journal Classification (ASJC) codes